Previous studies in TSC patients indicated that blood levels of tumor vascularization mediators are reduced in response to mTOR inhibitor therapy reflecting the strong effect on AML vascularization [7,14,15]. This evidence concerns the gene MTOR and acute myeloid leukemia.